If you follow the intricate world of global pharmaceuticals, you know Bangladesh is a major player. Thanks to the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) exemption, Bangladesh has become a global powerhouse in producing affordable, high-quality generic drugs.
However, there's a serious underlying vulnerability. And the Alliance for Health Reforms Bangladesh (AHRB) is ringing the alarm bell, demanding immediate implementation of the Active Pharmaceutical Ingredient (API) policy. Why the urgency? Let's break down why this affects more than just Bangladesh.
The Achilles' Heel: Why Local API Production Matters
An API is the core ingredient—the biologically active component—that makes a drug effective. Right now, even though Bangladesh excels at formulation (turning API into pills/liquids), it remains heavily reliant on imports, primarily from China and India, for the raw API itself.
Think of it this way: Bangladesh is an expert baker, but they have to import 95% of their flour from two suppliers. If those suppliers have a bad harvest, or face political roadblocks, the entire operation grinds to a halt.
The pandemic exposed this fragility globally. Supply chains fractured, costs skyrocketed, and sudden dependencies became lethal risks. This is precisely the dependency the AHRB is urging the government to shatter through swift policy implementation.
The AHRB’s Core Demands and the Economic Upside
The AHRB isn't just making noise; they are pointing to a clear, achievable roadmap. They argue that the policy framework has been established, but execution is lagging. The key focus areas include:
- Incentives for Local Investment: Providing tax breaks, subsidies, and duty waivers on machinery to encourage pharmaceutical companies to shift capital toward API manufacturing plants.
- Land Allocation and Infrastructure: Rapidly developing the designated API Industrial Park in Munshiganj, ensuring utility connections (gas, electricity, water) are functional and reliable immediately.
- Faster Regulatory Approval: Streamlining bureaucratic processes that currently delay the setup and certification of new API facilities.
The payoff is immense. Local API production not only guarantees domestic drug security but also allows Bangladeshi companies to compete on better margins internationally, boosting exports and strengthening the country’s crucial generic manufacturing sector.
Why the World is Watching
For the global community, Bangladesh’s success in implementing this policy is about supply chain diversification and resilience.
When a major generic drug manufacturer secures its supply line, it helps stabilize the global market for essential medicines. If Bangladesh can transition from a major generic formulator to a major generic producer, it provides a much-needed alternative source to the current giants.
AHRB Statement: “The policy is an economic blueprint for the next decade. Delaying its implementation is not just missing an opportunity; it’s inviting unnecessary risk to public health, both here and abroad.”
Moving Forward: Time is Not on Our Side
The professional consensus is unanimous: the API policy is crucial. The investment required is significant, but the long-term benefits of self-reliance, reduced import bills, and enhanced competitiveness far outweigh the initial capital outlay.
The call from the Alliance for Health Reforms Bangladesh is a wake-up call to policymakers: Act now to secure the future of the nation’s most successful industrial sector and solidify its role as a stable provider of global health solutions.
.png)
0 Comments